FDA approves first interchangeable biosimilar for inflammatory diseases
(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),
Updated on: June 17,2024
FDA approves first interchangeable biosimilar for inflammatory diseases
(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),
Updated on:June 17,2024
